Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data
Elizabeth Dudnik(Rabin Medical Center), Nir Peled(Shaare Zedek Medical Center), Laila C. Roisman(Shaare Zedek Medical Center), Sivan Shamai(Tel Aviv Sourasky Medical Center), Daniel A. Goldstein(Rabin Medical Center), Ekaterina Hanovich(Assaf Harofeh Medical Center), Ahuva Grubstein(Rabin Medical Center), Yelena Shechtman(Rambam Health Care Campus), Ofer Merimsky(Tel Aviv Sourasky Medical Center), Tzippy Shochat(Rabin Medical Center), Ariel Hammerman(Clalit Health Services), Alona Zer(Rambam Health Care Campus), Dov Flex(Rabin Medical Center), Mira Wollner(Technion – Israel Institute of Technology), Arnold Cyjon(Ontario Institute for Cancer Research), Mor Moskovitz(Rambam Health Care Campus), Jair Bar(Tel Aviv University), Sameh Daher(Sheba Medical Center), Mahmood Abu-Amna(Rambam Health Care Campus)
Cited by 104
Related Papers
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|751
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661